<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02734602</url>
  </required_header>
  <id_info>
    <org_study_id>1511016789</org_study_id>
    <nct_id>NCT02734602</nct_id>
  </id_info>
  <brief_title>Imaging SV2A in Mood Disorders</brief_title>
  <official_title>Imaging SV2A in Mood Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to examine SV2A density in MDD and PTSD as a correlate of synaptic&#xD;
      density, and to determine whether ketamine administration will reverse the synaptic loss in&#xD;
      vivo in human subjects. To our knowledge, this is the first human study to examine SV2A in&#xD;
      vivo in MDD and PTSD and to use the first known drug (ketamine) that rapidly reverses&#xD;
      synaptic loss to determine whether ketamine administration could restore some of the&#xD;
      structural changes associated with depression and PTSD.&#xD;
&#xD;
      After a screening process to determine eligibility, all subjects will participate in an MRI,&#xD;
      and 2-3 PET scans with the administration of ketamine for one of the scans. Cognitive testing&#xD;
      and a stress test may also be done on scan days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of the study is to determine whether there are alterations in synaptic vesicle&#xD;
      glycoprotein 2A (SV2A), a protein expressed ubiquitously in synaptic vesicles, in depression&#xD;
      and anxiety and whether ketamine, an N-Methyl-D-aspartate (NMDA) antagonist, normalizes SV2A&#xD;
      density at time of its greatest anti-depressant response. This study will conduct an&#xD;
      examination of SV2A and associated consequences using neuroreceptor imaging and behavioral&#xD;
      techniques for the following aims.&#xD;
&#xD;
      Aim 1: To compare SV2A availability in individuals with MDD, healthy control individuals, and&#xD;
      individuals with PTSD using APP311 and PET.&#xD;
&#xD;
      Hypothesis 1: This study hypothesizes lower SV2A density in MDD and PTSD in the prefrontal&#xD;
      cortex.&#xD;
&#xD;
      Aim 2: To determine whether ketamine administration alters SV2A density in HC, MDD, and PTSD&#xD;
      individuals. Note: this arm is completed.&#xD;
&#xD;
      Hypothesis 2: This study hypothesizes administration of ketamine will lead to a significant&#xD;
      increase in SV2A density in all subject groups (HC, MDD, and PTSD), and this increase will&#xD;
      correlate with antidepressant response in individuals with MDD.&#xD;
&#xD;
      New Aim pending.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of synaptic changes in psychiatric disorders confirmed by PET data.</measure>
    <time_frame>Through study completion date, an average of 5 years.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of synaptic density at time of its greatest anti-depressant response in psychiatric disorders confirmed with PET data.</measure>
    <time_frame>Through study completion date, an average of 5 years.</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Post-Traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Cognitive Testing</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will take part in verbal assessments as well as computer testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnetic Resonance Imaging</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anatomical MRIs will be performed on a Siemens 3T Trio at Yale. We will acquire the following: structural MRI, resting state MRI, diffusion tensor imaging data (DTI), and arterial spin labeling (ASL). We may also ask subjects to complete an emotional capture task.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positron Emission Tomography</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will participate in 2-3 PET scans (up to 4 if cancelations occur) on the High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or the HR+ will be used to image subjects. Vital signs (blood pressure and pulse) will be obtained before and after radiotracer administration. Venous catheter(s) will be used for IV administration of the radiotracer and for venous blood sampling. An arterial catheter will be inserted by an experienced physician before the PET scan. After a baseline scan, subjects will be administered a low dose of ketamine for the second scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Ketamine will be administered after the initial PET scan.</description>
    <arm_group_label>Positron Emission Tomography</arm_group_label>
    <other_name>Ket</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Testing</intervention_name>
    <description>Verbal and computer assessments will be given.</description>
    <arm_group_label>Cognitive Testing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PET</intervention_name>
    <description>PET scan will involve infusion of a radiotracer.</description>
    <arm_group_label>Positron Emission Tomography</arm_group_label>
    <other_name>Positron Emission Tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Anatomical MRIs will be performed on a Siemens 3T Trio at Yale.</description>
    <arm_group_label>Magnetic Resonance Imaging</arm_group_label>
    <other_name>Magnetic Resonance Imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  General inclusion criteria:&#xD;
&#xD;
               1. Subjects will be 18-70 years old,&#xD;
&#xD;
               2. English speaking,&#xD;
&#xD;
               3. No other DSM-5 diagnosis present, besides required as below.&#xD;
&#xD;
        Inclusion criteria for depressed subjects:&#xD;
&#xD;
          1. Meet DSM-5 diagnostic criteria for Major Depressive Disorder, and for a current&#xD;
             depressive episode.&#xD;
&#xD;
          2. Treatment or non-treatment seeking who understand that this study is for research&#xD;
             purposes only.&#xD;
&#xD;
        Inclusion criteria for healthy controls:&#xD;
&#xD;
        1. No current, or history of any DSM-5 diagnosis.&#xD;
&#xD;
        Inclusion criteria for PTSD subjects:&#xD;
&#xD;
        1. Current Post Traumatic Stress Disorder.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of significant medical illness that would contraindicate study participation&#xD;
             based on above criteria and PI/MD history review.&#xD;
&#xD;
          2. Lifetime history of neurologic abnormality including seizure disorder, cerebrovascular&#xD;
             or neoplastic lesion, neurodegenerative disorder, or significant head trauma resulting&#xD;
             in post-traumatic amnesia &gt;24 hours.&#xD;
&#xD;
          3. Full scale IQ lower than 70.&#xD;
&#xD;
          4. Contraindication to MRI scanning including claustrophobia and presence of a&#xD;
             ferromagnetic object, including orthodontic braces. All participants will be screened&#xD;
             for metal objects by the same methods used for routine clinical MRI scanning.&#xD;
&#xD;
          5. Pregnancy or breast-feeding.&#xD;
&#xD;
          6. Met DSM-5 criteria for mild substance use disorder (except nicotine and marijuana)&#xD;
             within the past 6 months or met DSM-5 criteria for moderate to severe substance use&#xD;
             disorder within the past year.&#xD;
&#xD;
          7. Current psychosis, active suicidal or homicidal ideation.&#xD;
&#xD;
          8. Positive urine toxicology screen (except for marijuana).&#xD;
&#xD;
          9. Contraindications to PET (e.g., past or current diagnosis of cancer, poor venous&#xD;
             access for placement of venous lines).&#xD;
&#xD;
         10. History of prior radiation exposure for research purposes within the past year such&#xD;
             that participation in this study would place them over FDA limits for annual radiation&#xD;
             exposure.&#xD;
&#xD;
         11. Previous or anticipated radiation exposure at work within one year of the proposed&#xD;
             research PET scans that precludes study participation.&#xD;
&#xD;
         12. Blood pressure &gt;130/80 (for Aim 2, ketamine challenge); blood pressure &gt;140/90&#xD;
             (non-ketamine groups).&#xD;
&#xD;
         13. History of a bleeding disorder or currently taking anticoagulants (such as Coumadin,&#xD;
             Heparin, Pradaxa, Xarelto).&#xD;
&#xD;
         14. Blood donation within eight weeks of the start of the study.&#xD;
&#xD;
         15. Current diagnosis of MDD or PTSD with psychotic features.&#xD;
&#xD;
         16. Hematocrit levels below 35 mg/dl, and/or hemoglobin levels below 10 mg/dl.&#xD;
&#xD;
         17. Weight under 110 lbs for subjects who will participate in portions of this study for&#xD;
             which the blood draw is at or above a typical blood donation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irina Esterlis, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah O, MA</last_name>
    <phone>203-737-7066</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole D</last_name>
    <phone>203-737-6884</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>PET Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah O, MA</last_name>
      <phone>203-737-7066</phone>
    </contact>
    <investigator>
      <last_name>Irina Esterlis, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 17, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Irina Esterlis</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>post-traumatic stress disorder</keyword>
  <keyword>sv2a</keyword>
  <keyword>ketamine</keyword>
  <keyword>PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

